Copy Link Print Information

Exatecan mesylate dihydrate

(Synonyms: DX-8951 mesylate dihydrate)
24 Cited Publications
Customer Review

Based on 24 publication(s) in Google Scholar

Exatecan (DX-8951) mesylate dihydrate is a DNA topoisomerase I inhibitor, with an IC50 of 2.2 μM (0.975 μg/mL), and can be used in cancer research.

For research use only. We do not sell to patients.

  • CAS No.: 197720-53-9
  • Formula: C24H22FN3O4S.CH4O3S.2H2O
  • Molecular Weight:567.58
  • Storage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Exatecan mesylate dihydrate Chemical Structure
    Exatecan mesylate dihydrate Chemical Structure
  • Experimental Validation Results for Exatecan mesylate dihydrate
  • Experimental Validation Results for Exatecan mesylate dihydrate
  • Experimental Validation Results for Exatecan mesylate dihydrate
  • Experimental Validation Results for Exatecan mesylate dihydrate
  • Experimental Validation Results for Exatecan mesylate dihydrate
  • Experimental Validation Results for Exatecan mesylate dihydrate
  • Experimental Validation Results for Exatecan mesylate dihydrate
CAS No.: 197720-53-9
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Exatecan mesylate dihydrate:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Purity & Documentation
  • References
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Exatecan mesylate dihydrate

More
Customer Validation & Images
WBIn Vivo Efficacy StudyCell Proliferation/Viability AssayHistological Imaging/StainingPK/PD AnalysisCell Imaging/Staining
  • WB
  • In Vivo Efficacy Study
  • Cell Proliferation/Viability Assay
  • Histological Imaging/Staining
  • PK/PD Analysis
  • Cell Imaging/Staining
  • Cell Proliferation/Viability Assay

All ADC Payloads Isoforms

More

All Topoisomerase Isoforms

More
Keywords
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Exatecan mesylate dihydrate Chemical Structure
    Exatecan mesylate dihydrate Chemical Structure
    1/16
  • 1/16

    Exatecan mesylate dihydrate purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2025 Oct 13;24(1):253. [Abstract]

    Customer Validation
     Western blot analysis of B1-5V (BRCA1-) and B2-4V (BRCA2-) cells treated with PBS (NT, no treatment), V66-exatecan (100 nM) ADC for 1-24 h, or V66 alone (24 h). In samples treated with V66-exatecan ADC, a time-dependent accumulation of DNA damage is observed, as indicated by the increased γH2AX and pATM signals, along with a time-dependent down-regulation of TOP1.

  • 1/16

    Exatecan mesylate dihydrate purchased from MedChemExpress. Usage Cited in: Mol Cancer Ther. 2023 Sep 5;22(9):1013-1027. [Abstract]

    Customer Validation
     In vivo efficacy of AMT-562, Ab562-T1000-Exatecan (10 mg/kg; i.v.), and P-GGFG-DXd in PC9 xenograft model.

  • 1/16

    Exatecan mesylate dihydrate purchased from MedChemExpress. Usage Cited in: Mol Cancer Ther. 2023 Sep 5;22(9):1013-1027. [Abstract]

    Customer Validation
     In vitro cytotoxicity of Exatecan and DXd in HER3-expressing cells. Cells were incubated with a concentration series of Exatecan or DXd for 5 days. Cell viability was measured by CCK-8 and IC50 for each cell line was calculated from cell viability-concentration plot.

  • 1/16

    Exatecan mesylate dihydrate purchased from MedChemExpress. Usage Cited in: Mol Cancer Ther. 2023 Sep 5;22(9):1013-1027. [Abstract]

    Customer Validation
     Representative hematoxylin and eosin staining of toxicity organs of AMT-562 and Ab562-T1000-Exatecan (ADC; 30 mg/kg; i.v.). Scale bar, 200 mm.

  • 1/16

    Exatecan mesylate dihydrate purchased from MedChemExpress. Usage Cited in: Mol Cancer Ther. 2023 Sep 5;22(9):1013-1027. [Abstract]

    Customer Validation
     Single dose pharmacokinetic profiles of AMT-562 (ADC) and Ab562-GGFG-DXd in mice. ADCs were intravenously administered to mice at the dose of 10 mg/kg.

  • 1/16

    Exatecan mesylate dihydrate purchased from MedChemExpress. Usage Cited in: Mol Cancer Ther. 2023 Sep 5;22(9):1013-1027. [Abstract]

    Customer Validation
     Patient-derived colon cancer organoids response to AMT-562 (ADC) and P-GGFG-DXd. Representative images of brightfield (left) and live/dead cells (right) for CO117 was shown. Colon cancer PDOs were treated with AMT-562 or P-GGFG-DXd at a serial concentration for 6 days. Live cells were stained by Calcein AM (green) and dead cells by PI (red).

  • 1/16

    Exatecan mesylate dihydrate purchased from MedChemExpress. Usage Cited in: Pharmaceuticals (Basel). 2021 Mar 9;14(3):247. [Abstract]

    Customer Validation
     Tra-Exa-PSAR10 and Tra-Exa-PSAR0 (0.01-10 nM, 6 days). In vitro cytotoxicity of ADCs in breast and gastric HER2+ and HER2- (MCF-7) cancer cell lines after 6-day exposure to trastuzumab conjugates, as assayed by MTT assay, n = 3.

  • Exatecan mesylate dihydrate